WO2011125484A1 - ヘモグロビン類の分析方法 - Google Patents
ヘモグロビン類の分析方法 Download PDFInfo
- Publication number
- WO2011125484A1 WO2011125484A1 PCT/JP2011/056816 JP2011056816W WO2011125484A1 WO 2011125484 A1 WO2011125484 A1 WO 2011125484A1 JP 2011056816 W JP2011056816 W JP 2011056816W WO 2011125484 A1 WO2011125484 A1 WO 2011125484A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- eluent
- hemoglobin
- sample
- measurement sample
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/067—Preparation by reaction, e.g. derivatising the sample
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
Definitions
- the present invention relates to a hemoglobin analysis method for separating hemoglobins by liquid chromatography.
- HPLC high-performance liquid chromatography
- hemoglobin A1c is a type of glycohemoglobin, analysis of abnormal hemoglobin, and the like in diabetes diagnosis.
- liquid chromatography is known in which hemoglobins in a measurement sample prepared by hemolyzing a blood sample are separated by a cation exchange method using a difference in positive charge state that differs for each hemoglobin component.
- the number of diabetic patients has increased in recent years, the number of hemoglobin A1c measurements has been increasing, and high precision measurement and shortening of the measurement time are also required in HPLC measurement.
- hemoglobins include oxyhemoglobin to which oxygen is bound, deoxyhemoglobin to which carbon dioxide is bound, and methemoglobin in which iron contained in heme is oxidized to form trivalent iron ions.
- HPLC using cation exchange chromatography the elution time of oxyhemoglobin, deoxyhemoglobin, and methemoglobin varies depending on the retention capacity of the separation column, and the detected elution peak broadens or shows bimodality. As a result, the separation accuracy may be poor.
- methemoglobin coexists with azide or cyanide
- azide or cyanide binds to trivalent iron ions of methemoglobin and azidomethemoglobin or cyanmethemoglobin (hereinafter, these are stabilized).
- This stabilized methemoglobin is also known to be stabilized, but the retention of the stabilized methemoglobin is slightly different from that of oxyhemoglobin and deoxyhemoglobin.
- the detected elution peak may be broadened or bimodal.
- hemoglobin S is the most common abnormal hemoglobin, and is a causative agent of sickle cell disease causing severe anemia, so that the demand for separation and detection is high.
- hemoglobin A1c which is a marker of diabetes
- degraded blood tends to generate broader or bimodal elution peaks than fresh blood. This is caused by an increase in methemoglobin caused by deterioration. For this reason, there is a concern about the influence on the measured value when the stored sample is analyzed by retesting or the like.
- Patent Document 1 discloses albumin.
- Patent Document 2 discloses a method of coexisting hemoglobins with casein, boric acid and the like
- Patent Document 3 discloses a method of coexisting hemoglobins with iminocarboxylic acid and a salt thereof.
- a degasser for removing gas in the eluent is incorporated in a general HPLC apparatus, but the degasser does not stabilize the gas removal capacity for a while after startup, and the elution time of hemoglobin varies. May adversely affect separation.
- the elution time of hemoglobin varies, and the quantitative property tends to deteriorate. This leads to a long time until the first report in a diabetes test using hemoglobin A1c as a marker, which requires quickness. Therefore, a technique that enables stable measurement immediately after the start-up of the HPLC apparatus is required. ing.
- the absorbance by a spectrophotometer is generally used for detection and quantification of various hemoglobins, oxyhemoglobin, deoxyhemoglobin, methemoglobin, azidomethemoglobin, and cyanmethemoglobin have different absorption spectra. If these are mixed, an accurate amount of hemoglobin may not be measured.
- An object of the present invention is to provide a method for analyzing hemoglobin capable of separating hemoglobin with high accuracy in a short time by liquid chromatography.
- the present invention is a method for analyzing hemoglobin using liquid chromatography, wherein the sample is previously treated with an oxidizing agent and a binder to trivalent heme iron.
- the present invention is described in detail below.
- the present inventors previously processed the specimen with an oxidizing agent and a binding agent to trivalent heme iron, thereby changing all the hemoglobins in the specimen to stabilized methemoglobin, and applying each hemoglobin to the column stationary phase.
- the inventors have found that hemoglobins can be separated with high holding force and high accuracy in a short time, and the present invention has been completed.
- the specimen is previously treated with an oxidizing agent and a binding agent to trivalent heme iron.
- the elution time of hemoglobin can be shortened while improving the separation of hemoglobin.
- the gas removal capability immediately after the startup of the degasser of the HPLC apparatus is not stable, the elution time of hemoglobins does not change, and the detected elution peak becomes broad or bimodal. And hemoglobins are separated with high accuracy.
- pretreating the specimen with an oxidizing agent and a binding agent to trivalent heme iron means that the specimen is separated from the oxidizing agent and trivalent heme before the hemoglobin is separated on the separation column.
- the hemoglobins are separated by blending an oxidizing agent and a binder to trivalent heme iron in any one of the combinations shown in Table 1 in the sample pretreatment liquid and / or eluent.
- the analyte can be treated with an oxidizing agent and a binder to trivalent heme iron before being processed.
- the oxidizing agent changes the hemoglobin of hemoglobin from divalent to trivalent to form methemoglobin.
- the oxidizing agent is not particularly limited as long as it has the effect of changing the hemoglobin heme iron from divalent to trivalent, and examples thereof include nitrite, potassium ferricyanide, methylene blue, hydrogen peroxide, ascorbic acid, hydrogen sulfide and the like. It is done. Of these, nitrite is preferable, and sodium nitrite and potassium nitrite are more preferable.
- hemoglobins will not be decomposed due to too strong oxidizing power, and the elution pattern will change greatly by binding to methemoglobin, and the wavelength and oxidation to detect hemoglobins.
- the absorption spectrum of the agent does not interfere with the fluctuation of the baseline during the HPLC measurement, and the quantification of the hemoglobin is excellent.
- the binding agent to trivalent heme iron turns methemoglobin into stabilized methemoglobin.
- the binder to trivalent heme iron include azide and cyanide.
- azides include sodium azide, diphenyl phosphate azide, 4-dodecylbenzenesulfonyl azide, 4-acetylaminobenzenesulfonyl azide, potassium azide, lithium azide, iron azide, hydrogen azide, and lead azide.
- the cyanide include potassium cyanide, hydrogen cyanide, sodium cyanide, silver cyanide, mercury cyanide, copper cyanide, lead cyanide, iron cyanide, lithium cyanide, ammonium cyanide and the like.
- sodium azide is preferable.
- a known buffer solution containing a buffering agent such as an organic acid or a salt thereof, an amino acid, an inorganic acid or a salt thereof, or a Good's buffer can be used.
- the organic acid include citric acid, succinic acid, tartaric acid, malic acid and the like.
- amino acids include glycine, taurine, arginine and the like.
- inorganic acids include hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, boric acid, acetic acid and the like.
- a surfactant, various polymers, a hydrophilic low molecular compound, and the like may be appropriately added to the buffer solution as necessary.
- the concentration of the buffer in the sample pretreatment solution is not particularly limited, but a preferable lower limit is 5 mmol / L, and a preferable upper limit is 500 mmol / L. If the buffer concentration is less than 5 mmol / L, the buffering action may not be sufficiently obtained. If the buffer concentration exceeds 500 mmol / L, precipitation of the buffer may occur, which may cause clogging of the flow path of the HPLC apparatus.
- a more preferable lower limit of the buffering agent concentration is 10 mmol / L, and a more preferable upper limit is 200 mmol / L.
- the concentration of the oxidizing agent in the specimen pretreatment liquid is not particularly limited, but a preferred lower limit is 0.05 mmol / L and a preferred upper limit is 50 mmol / L. If the concentration of the oxidant in the sample pretreatment liquid is less than 0.05 mmol / L, the hemoglobins are not sufficiently met and detected by mixing oxyhemoglobin and deoxyhemoglobin in the measurement sample.
- the elution peak may be broad or bimodal.
- concentration of the oxidizing agent in the sample pretreatment liquid exceeds 50 mmol / L, methemoglobin is decomposed, and the elution peak may not be detected or the elution peak may be detected at a different elution time.
- a more preferable lower limit of the concentration of the oxidizing agent in the specimen pretreatment liquid is 0.5 mmol / L, and a more preferable upper limit is 25 mmol / L.
- the concentration of the binder to trivalent heme iron in the sample pretreatment liquid is not particularly limited, but the preferred lower limit is 0.05 mmol / L.
- the preferred upper limit is 50 mmol / L.
- concentration of the binding agent to trivalent heme iron in the sample pretreatment solution exceeds 50 mmol / L, methemoglobin is decomposed and no elution peak is detected or an elution peak is detected at a different elution time.
- concentration of the binder to trivalent heme iron in the sample pretreatment liquid is 0.5 mmol / L, and a more preferable upper limit is 25 mmol / L.
- the pH of the sample pretreatment liquid is not particularly limited, but a preferable lower limit is 4.0 and a preferable upper limit is 10.0. If the pH of the sample pretreatment solution is less than 4.0 or more than 10.0, the stability of hemoglobin may be reduced, and the elution peak may not be detected, or the elution peak may be detected at a different elution time. .
- the more preferable lower limit of the pH of the sample pretreatment liquid is 6.0, and the more preferable upper limit is 8.5.
- a known buffer containing a buffer such as an organic acid or a salt thereof, an amino acid, an inorganic acid or a salt thereof, and Good's buffer can be used.
- the organic acid include citric acid, succinic acid, tartaric acid, malic acid and the like.
- amino acids include glycine, taurine, arginine and the like.
- inorganic acids include hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, boric acid, acetic acid and the like.
- surfactant, various polymers, a hydrophilic low molecular weight compound, etc. may be suitably added to the buffer solution as needed.
- the buffer concentration of the eluent is not particularly limited, but a preferred lower limit is 5 mmol / L and a preferred upper limit is 500 mmol / L. If the buffer concentration is less than 5 mmol / L, the buffering action may not be sufficiently obtained. If the concentration of the buffer exceeds 500 mmol / L, it may cause precipitation of the buffer and cause clogging of the flow path of the HPLC apparatus, or it may cause the switching efficiency of the eluent to decrease and take time for equilibration. Sometimes. A more preferable lower limit of the buffering agent concentration is 10 mmol / L, and a more preferable upper limit is 200 mmol / L.
- the concentration of the oxidizing agent in the eluent is not particularly limited, but the preferred lower limit is 0.05 mmol / L and the preferred upper limit is 50 mmol / L. If the concentration of the oxidant in the eluent is less than 0.05 mmol / L, hemoglobins are not sufficiently metomorphized, and oxyhemoglobin and deoxyhemoglobin are mixed in the measurement sample, so that the elution peak broadens. Or bimodality. When the concentration of the oxidizing agent in the eluent exceeds 50 mmol / L, the elution time becomes too early and the resolution may deteriorate.
- the elution time can be adjusted by adjusting the concentration of the buffer in the eluent within a range where methemoglobin is not degraded.
- a more preferable lower limit of the concentration of the oxidizing agent in the eluent is 0.5 mmol / L, and a more preferable upper limit is 25 mmol / L.
- the concentration of the binder to trivalent heme iron in the eluent is not particularly limited, but the preferred lower limit is 0.05 mmol / L, and the preferred upper limit is 50 mmol / L.
- concentration of the binding agent to trivalent heme iron in the eluent is less than 0.05 mmol / L, hemoglobins are not sufficiently met and the elution peak is caused by the mixture of oxyhemoglobin and deoxyhemoglobin. May become broad or bimodal.
- the concentration of the binder to the trivalent heme iron in the eluent exceeds 50 mmol / L, the elution time may be too fast and the resolution may deteriorate.
- the elution time can be adjusted by adjusting the concentration of the buffer in the eluent within a range where methemoglobin is not degraded.
- a more preferable lower limit of the concentration of the binder to trivalent heme iron in the eluent is 0.5 mmol / L, and a more preferable upper limit is 25 mmol / L.
- the oxidizing agent and trivalent are added to the eluent sent at least at the beginning of the measurement by HPLC.
- a binder to heme iron is added.
- the oxidizing agent and the binding agent to trivalent heme iron are preferably added to the eluent other than the eluent sent at the beginning of the measurement by HPLC, and should be added to all eluents used for the measurement. Is more preferable.
- the eluent may contain a known acid or base as a pH adjuster.
- the acid include hydrochloric acid, phosphoric acid, nitric acid, sulfuric acid and the like
- the base include sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, barium hydroxide, calcium hydroxide and the like. Can be mentioned.
- the eluent may contain a water-soluble organic solvent such as methanol, ethanol, acetonitrile, and acetone.
- concentration of the organic solvent is preferably such that no salt or the like is precipitated, and the preferable upper limit is 80% (v / v).
- the pH of the eluent is not particularly limited, but a preferred lower limit is 4.0 and a preferred upper limit is 10.0. If the pH of the eluent is less than 4.0, the reading of the detected elution peak may become large, or the elution peak may become broad or bimodal. When the pH of the eluent exceeds 10.0, the retention of the column stationary phase and hemoglobin is weakened, and the elution time of hemoglobin becomes extremely fast, and the tailing of the detected elution peak becomes large. The elution peak may be broad or bimodal.
- the stability of hemoglobins in the measurement sample does not decrease, the hemoglobin elution peaks are not detected, or the elution peaks are at different elution times. Will not be detected.
- a more preferred lower limit of the pH of the eluent is 6.0, and a more preferred upper limit is 8.5.
- liquid chromatography in the method for analyzing hemoglobin of the present invention, it is preferable to use ion exchange liquid chromatography.
- ion exchange liquid chromatography a known method can be used. For example, when an eluent is sent to a separation column using a pump, the eluent is passed through a degasser, and then a measurement sample is injected and sent to the separation column, and hemoglobins are separated and separated by the separation column. And a method of detecting the separated components in the eluate with a detector.
- the separation column is a column body filled with a stationary phase.
- the stationary phase include filler particles and porous bodies. Among these, filler particles are preferable.
- the filler particles include inorganic particles and organic particles. Examples of the inorganic particles include particles composed of silica, zirconia, and the like. Examples of the organic particles include natural polymer particles such as cellulose, polyamino acid, and chitosan, and synthetic polymer particles such as polystyrene and polyacrylate.
- the stationary phase it is preferable to use a stationary phase having a cation exchange group.
- the cation exchange group include a carboxyl group, a phosphate group, and a sulfonate group.
- the measurement conditions in the hemoglobin analysis method of the present invention can be appropriately selected depending on the type of measurement sample, column, etc. used.
- the preferred lower limit of the eluent flow rate is 0.05 mL / min, and the preferred upper limit is 5 mL / min.
- a preferable lower limit is 0.2 mL / min, and a more preferable upper limit is 3 mL / min.
- the detection wavelength of hemoglobins is preferably 415 nm, but is not particularly limited thereto.
- As the measurement sample a sample obtained by diluting a hemolyzed blood sample with a solution containing a substance having hemolytic activity such as a surfactant is usually used.
- the injection amount of the measurement sample varies depending on the dilution rate of the blood sample, but is preferably about 0.1 to 100 ⁇ L.
- the method for analyzing hemoglobin of the present invention exhibits excellent separation ability, enables analysis to be performed in a short time, and facilitates separation of hemoglobin that has been difficult to separate. That is, according to the present invention, hemoglobins can be separated and analyzed with high accuracy in a short time by liquid chromatography.
- Example 2 it is the chromatogram obtained by measuring the measurement sample containing the blood containing (a) glycohemoglobin control level 2 and (b) hemoglobin S.
- Example 3 it is the chromatogram obtained by measuring (a) the measurement sample containing the glycohemoglobin control level 2, and (b) the measurement sample containing the blood containing hemoglobin S.
- Example 4 it is the chromatogram obtained by measuring (a) the measurement sample containing the glycohemoglobin control level 2, and (b) the measurement sample containing the blood containing hemoglobin S.
- Example 5 it is the chromatogram obtained by measuring (a) the measurement sample containing the glycohemoglobin control level 2 and (b) the measurement sample containing the blood containing hemoglobin S.
- Example 6 it is the chromatogram obtained by measuring (a) the measurement sample containing the glycohemoglobin control level 2, and (b) the measurement sample containing the blood containing hemoglobin S.
- Example 7 it is the chromatogram obtained by measuring (a) the measurement sample containing the glycohemoglobin control level 2 and (b) the measurement sample containing the blood containing hemoglobin S.
- Example 8 it is a chromatogram obtained by measuring (a) a measurement sample containing glycated hemoglobin control level 2 and (b) a measurement sample containing blood containing hemoglobin S.
- Comparative Example 2 it is a chromatogram obtained by measuring (a) a measurement sample containing glycohemoglobin control level 2 and (b) a measurement sample containing blood containing hemoglobin S.
- Comparative Example 3 it is a chromatogram obtained by measuring (a) a measurement sample containing glycohemoglobin control level 2 and (b) a measurement sample containing blood containing hemoglobin S.
- Example 4 (a) a chromatogram obtained by measuring a measurement sample containing glycated hemoglobin control level 2 and (b) a measurement sample containing blood containing hemoglobin S.
- Example 9 it is the chromatogram obtained by measuring (a) the measurement sample containing the glycohemoglobin control level 2, and (b) the measurement sample containing the blood containing hemoglobin S.
- Example 10 it is the chromatogram obtained by measuring (a) the measurement sample containing the glycohemoglobin control level 2, and (b) the measurement sample containing the blood containing hemoglobin S.
- Example 1 A blood sample containing hemoglobin S diluted 100-fold with a sample pretreatment solution (phosphate buffer solution (pH 7.0) containing 0.1 wt% Triton X-100) was used as a measurement sample.
- a sample pretreatment solution phosphate buffer solution (pH 7.0) containing 0.1 wt% Triton X-100
- a separation column a column in which a cation exchange resin filler having a sulfonic acid group introduced on the particle surface was packed in the column body was used.
- SIL-20AC manufactured by Shimadzu Corporation
- LC-20AD manufactured by Shimadzu Corporation
- DGU-20A5 manufactured by Shimadzu Corporation
- CTO-20AC column oven SPD-M20A (manufactured by Shimadzu Corporation)
- the flow rate of the eluent was 1.7 mL / min
- the detection wavelength was 415 nm
- the measurement sample injection volume was 10 ⁇ L.
- eluent 1 As an eluent, eluent 1 (60 mmol / L sodium perchlorate, 1 mmol / L sodium nitrite, 1 mmol / L sodium azide-containing 40 mmol / L phosphate buffer (pH 5.4) is used for up to 0.5 minutes.
- Example 1 The measurement sample was the same as in Example 1. Eluent 1 was used as eluent 4 (60 mmol / L sodium perchlorate, 40 mmol / L phosphate buffer (pH 5.4) containing 1 mmol / L sodium azide), and eluent 2 was used as eluent 5 (10 mmol / L excess). The measurement sample was measured in the same manner as in Example 1 except that it was changed to sodium chlorate and 20 mmol / L phosphate buffer (pH 7.0) containing 1 mmol / L sodium azide.
- Example 1 The relationship between the number of measurements in Example 1 and Comparative Example 1 and the elution time of hemoglobin S is shown in FIG. 1 that the elution time of hemoglobin S is delayed in the comparative example 1 as the number of measurements is increased. On the other hand, in Example 1, the hemoglobin S elution time was almost constant regardless of the number of measurements.
- Example 2 Glycohemoglobin control level 2 (manufactured by Sysmex) was dissolved in 200 ⁇ L of water for injection, and then a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100)) A 100-fold diluted sample was used as a measurement sample. A blood sample containing hemoglobin S diluted 100-fold with a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100) was used as a measurement sample. Using. As the separation column, the same separation column as in Example 1 was used.
- the same HPLC apparatus as in Example 1 was used, the flow rate was 1.7 mL / min, the detection wavelength was 415 nm, and the measurement sample injection volume was 10 ⁇ L.
- the eluent is eluent 6 (30 mmol / L sodium perchlorate, 1 mmol / L sodium nitrite, 1 mmol / L sodium azide-containing 20 mmol / L phosphate buffer (pH 5.4)) as the first eluent.
- eluent 7 As the second eluent, eluent 7 (0.8 mmol% Triton X-100, 300 mmol / L sodium perchlorate, 1 mmol / L sodium nitrite, 1 mmol / L sodium azide 40 mmol / L phosphate buffer ( The sample to be measured was eluted with a two-liquid linear gradient using pH 8.0). The gradient conditions of the first eluent and the second eluent are shown in FIG. FIG. 2 shows the ratio (% by weight) of the second eluent to the total amount of the first eluent and the second eluent. The obtained chromatogram is shown in FIG.
- Example 3 Glycohemoglobin control level 2 (manufactured by Sysmex Corporation) was dissolved in 200 ⁇ L of water for injection, and sample pretreatment solution (containing 0.1 wt% Triton X-100, 1 mmol / L sodium nitrite, 1 mmol / L sodium azide) 10 mmol / L phosphate buffer (pH 7.0) diluted 100 times was used as a measurement sample.
- sample pretreatment solution containing 0.1 wt% Triton X-100, 1 mmol / L sodium nitrite, 1 mmol / L sodium azide-containing 10 mmol / L phosphate buffer (pH 7.
- the second eluent was used as eluent 3 (0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 1 mmol / L sodium azide 40 mmol / L phosphate buffer ( The measurement sample was measured in the same manner as in Example 2, except that the pH was changed to 8.0). The obtained chromatogram is shown in FIG.
- Example 4 Glycohemoglobin control level 2 (manufactured by Sysmex) was dissolved in 200 ⁇ L of water for injection, and then a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100)) A 100-fold diluted sample was used as a measurement sample. A blood sample containing hemoglobin S diluted 100-fold with a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100) was used as a measurement sample. Using.
- the first eluent was changed to eluent 8 (30 mmol / L sodium perchlorate, 10 mmol / L sodium nitrite, 20 mmol / L phosphate buffer (pH 5.4) containing 1 mmol / L sodium azide),
- the second eluent was eluent 9 (0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 10 mmol / L sodium nitrite, 1 mmol / L sodium azide 40 mmol / L phosphate buffer.
- the measurement sample was measured in the same manner as in Example 2 except that the pH was changed to (pH 8.0). The obtained chromatogram is shown in FIG.
- Example 5 Glycohemoglobin control level 2 (manufactured by Sysmex) was dissolved in 200 ⁇ L of water for injection, and then a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100)) A 100-fold diluted sample was used as a measurement sample. A blood sample containing hemoglobin S diluted 100-fold with a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100) was used as a measurement sample. Using.
- the first eluent was changed to eluent 10 (30 mmol / L sodium perchlorate, 1 mmol / L sodium nitrite, 20 mmol / L phosphate buffer (pH 5.4) containing 10 mmol / L sodium azide),
- the second eluent was used as eluent 11 (0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 1 mmol / L sodium nitrite, 10 mmol / L sodium azide 40 mmol / L phosphate buffer
- the measurement sample was measured in the same manner as in Example 2 except that the pH was changed to (pH 8.0). The obtained chromatogram is shown in FIG.
- Example 6 Glycohemoglobin control level 2 (manufactured by Sysmex) was dissolved in 200 ⁇ L of water for injection, and then a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100)) A 100-fold diluted sample was used as a measurement sample. A blood sample containing hemoglobin S diluted 100-fold with a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100) was used as a measurement sample. Using.
- the first eluent was changed to eluent 12 (30 mmol / L sodium perchlorate, 10 mmol / L sodium nitrite, 20 mmol / L phosphate buffer (pH 5.4) containing 10 mmol / L sodium azide),
- the second eluent was used as eluent 13 (0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 10 mmol / L sodium nitrite, 10 mmol / L sodium azide 40 mmol / L phosphate buffer
- the measurement sample was measured in the same manner as in Example 2 except that the pH was changed to (pH 8.0). The obtained chromatogram is shown in FIG.
- Example 7 Glycohemoglobin control level 2 (manufactured by Sysmex Corporation) is dissolved in 200 ⁇ L of water for injection, and then a sample pretreatment solution (0.1 wt% Triton X-100, 1 mmol / L potassium ferricyanide, 1 mmol / L sodium azide is contained. What was diluted 100 times with 10 mmol / L phosphate buffer (pH 7.0) was used as a measurement sample.
- a sample pretreatment solution 0.1 wt% Triton X-100, 1 mmol / L potassium ferricyanide, 1 mmol / L sodium azide is contained. What was diluted 100 times with 10 mmol / L phosphate buffer (pH 7.0) was used as a measurement sample.
- a blood sample containing hemoglobin S was prepared as a sample pretreatment solution (0.1 mmol% Triton X-100, 1 mmol / L potassium ferricyanide, 10 mmol / L phosphate buffer (pH 7.0) containing 1 mmol / L sodium azide). The sample diluted 100 times in step)) was used as a measurement sample.
- the first eluent was changed to eluent 14 (30 mmol / L sodium perchlorate, 1 mmol / L potassium ferricyanide, 20 mmol / L phosphate buffer (pH 5.4) containing 1 mmol / L sodium azide)
- Two eluents were added to eluent 15 (0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 1 mmol / L potassium ferricyanide, 1 mmol / L sodium azide 40 mmol / L phosphate buffer (pH 8 0.0)), the measurement sample was measured in the same manner as in Example 2. The obtained chromatogram is shown in FIG.
- Example 8 Glycohemoglobin control level 2 (manufactured by Sysmex) was dissolved in 200 ⁇ L of water for injection, and then a sample pretreatment solution (0.1 wt% Triton X-100, 10 mmol / L phosphate buffer containing 1 mmol / L sodium azide) A solution (pH 7.0) diluted 100 times was used as a measurement sample. In addition, a blood sample containing hemoglobin S is increased 100 times with a sample pretreatment solution (0.1 wt% Triton X-100, 10 mmol / L phosphate buffer (pH 7.0) containing 1 mmol / L sodium azide). The diluted sample was used as a measurement sample.
- a sample pretreatment solution 0.1 wt% Triton X-100, 10 mmol / L phosphate buffer (pH 7.0) containing 1 mmol / L sodium azide.
- the first eluent is changed to eluent 16 (30 mmol / L sodium perchlorate, 1 mmol / L sodium ferricyanide, 20 mmol / L phosphate buffer (pH 5.4) containing 1 mmol / L sodium azide).
- the second eluent was used as eluent 3 (0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 40 mmol / L phosphate buffer containing 1 mmol / L sodium azide used in Example 1).
- the measurement sample was measured in the same manner as in Example 2 except that the pH was changed to (pH 8.0). The obtained chromatogram is shown in FIG.
- the first eluent was changed to eluent 17 (30 mmol / L sodium perchlorate, 20 mmol / L phosphate buffer (pH 5.4) containing 1 mmol / L sodium azide) and the second eluent was run.
- Eluent 3 used in Example 1 (0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 40 mmol / L phosphate buffer (pH 8.0) containing 1 mmol / L sodium azide)
- the measurement sample was measured in the same manner as in Example 2 except that. The obtained chromatogram is shown in FIG.
- the first eluent was changed to eluent 18 (30 mmol / L sodium perchlorate, 20 mmol / L phosphate buffer (pH 5.4) containing 1 mmol / L sodium nitrite), and the second eluent was eluted. Except for changing to liquid 19 (0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 40 mmol / L phosphate buffer (pH 8.0) containing 1 mmol / L sodium nitrite). The measurement sample was measured in the same manner as in Example 2. The obtained chromatogram is shown in FIG.
- the first eluent was changed to eluent 20 (30 mmol / L sodium perchlorate, 20 mmol / L phosphate buffer (pH 5.4) containing 1 mmol / L potassium ferricyanide), and the second eluent was changed to eluent.
- Sample to be measured in the same manner as in Example 2 except that it was changed to 21 (0.8 wt% Triton X-100, 40 mmol / L phosphate buffer (pH 8.0) containing 300 mmol / L sodium perchlorate) was measured.
- the obtained chromatogram is shown in FIG.
- Example 9 Glycohemoglobin control level 2 (manufactured by Sysmex) was dissolved in 200 ⁇ L of water for injection, and then a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100)) A 100-fold diluted sample was used as a measurement sample. A blood sample containing hemoglobin S diluted 100-fold with a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100) was used as a measurement sample. Using.
- the first eluent was changed to eluent 22 (30 mmol / L sodium perchlorate, 25 mmol / L sodium nitrite, 20 mmol / L phosphate buffer (pH 5.4) containing 25 mmol / L sodium azide),
- the second eluent was used as eluent 23 (40 mmol / L phosphate buffer containing 0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 25 mmol / L sodium nitrite, 25 mmol / L sodium azide).
- the measurement sample was measured in the same manner as in Example 2 except that the pH was changed to (pH 8.0). The obtained chromatogram is shown in FIG.
- Example 10 Glycohemoglobin control level 2 (manufactured by Sysmex) was dissolved in 200 ⁇ L of water for injection, and then a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100)) A 100-fold diluted sample was used as a measurement sample. A blood sample containing hemoglobin S diluted 100-fold with a sample pretreatment solution (10 mmol / L phosphate buffer (pH 7.0) containing 0.1 wt% Triton X-100) was used as a measurement sample. Using.
- the first eluent was changed to eluent 24 (30 mmol / L sodium perchlorate, 50 mmol / L sodium nitrite, 20 mmol / L phosphate buffer (pH 5.4) containing 50 mmol / L sodium azide),
- the second eluent was used as eluent 25 (40 mmol / L phosphate buffer containing 0.8 wt% Triton X-100, 300 mmol / L sodium perchlorate, 50 mmol / L sodium nitrite, 50 mmol / L sodium azide).
- the measurement sample was measured in the same manner as in Example 2 except that the pH was changed to (pH 8.0). The obtained chromatogram is shown in FIG.
- Tables 2 and 3 show the compositions of the sample pretreatment liquid and the eluent used in the measurements of Examples 2 to 10 and Comparative Examples 2 to 4, respectively.
- Table 4 shows the separation state and peak pattern of hemoglobins in the obtained chromatogram.
- peak (A) indicates hemoglobin A0
- peak (B) indicates hemoglobin A2
- peak (C) indicates hemoglobin S.
- 3 to 7 it was confirmed that the peak (A) and the peak (C) were separated as a sharp single peak.
- FIG. 8 Example 7
- the peak (A) and the peak (C) in FIG. 9 Example 8) were detected as peaks having a slight trimodality or bimodality, but there was no problem.
Abstract
Description
また、新鮮血よりも劣化血の方がブロードや二峰性の溶出ピークを生じやすい傾向がある。これは劣化により生じるメトヘモグロビンが増加することが原因である。そのため、再検査等で保存検体の分析を行う場合に測定値への影響が懸念されている。
しかしながら、特許文献1~3に開示されている方法を用いても、血液検体にオキシヘモグロビン、デオキシヘモグロビン、メトヘモグロビン等の各種ヘモグロビン類が混在する状況においては、HPLCで測定した場合に溶出ピークがブロード化したり二峰性を示したりすることがある。
なお、各種ヘモグロビン類の検出、定量には一般的に分光光度計による吸光度が用いられるが、オキシヘモグロビン、デオキシヘモグロビン、メトヘモグロビン、アジドメトヘモグロビン、シアンメトヘモグロビンはそれぞれの吸光スペクトルが異なっているため、これらが混在していると正確なヘモグロビン量を測定することができないことがある。
以下に本発明を詳述する。
酸化剤及び三価のヘム鉄への結合剤で検体を処理することにより、ヘモグロビン類の分離能を向上させつつヘモグロビン類の溶出時間を短縮できる。更に、HPLC装置のデガッサーの立ち上げ直後の気体除去能力が安定しない場合においても、ヘモグロビン類の溶出時間の変動が発生しなくなるとともに、検出される溶出ピークがブロード化したり二峰性を示したりすることがなく、ヘモグロビン類が高精度に分離される。
なお、本発明において、「予め検体を酸化剤及び三価のヘム鉄への結合剤で処理する」とは、ヘモグロビン類が分離カラムで分離される前に、検体を酸化剤及び三価のヘム鉄への結合剤で処理することを意味し、液体クロマトグラフィーでの測定開始前に処理することに限定されない。具体的には例えば、検体前処理液及び/又は溶離液に、表1に記載した組み合わせのいずれかで酸化剤と三価のヘム鉄への結合剤とを配合することにより、ヘモグロビン類が分離される前に検体を酸化剤及び三価のヘム鉄への結合剤で処理できる。表1中、「○」は配合することを意味し、「-」は配合しないことを意味する。
酸化剤としては、ヘモグロビン類のヘム鉄を二価から三価に変化させる効果があれば特に限定されず、例えば、亜硝酸塩、フェリシアン化カリウム、メチレンブルー、過酸化水素、アスコルビン酸、硫化水素等が挙げられる。なかでも、亜硝酸塩が好適であり、亜硝酸ナトリウム、亜硝酸カリウムがより好適である。これらの酸化剤を用いることで、酸化力が強すぎてヘモグロビン類が分解したりすることがなく、また、メトヘモグロビンと結合して溶出パターンが大きく変化したり、ヘモグロビン類を検出する波長と酸化剤の吸光スペクトルが干渉してHPLC測定中にベースラインの変動が生じたりすることがなく、ヘモグロビン類の定量性により優れたものとなる。
三価のヘム鉄への結合剤としては、例えば、アジ化物、シアン化物等が挙げられる。三価のヘム鉄への結合剤としてアジ化物又はシアン化物を用いることにより、メトヘモグロビンの構造を大きく変えてしまうことがなく、ヘモグロビン類の溶出挙動を大きく変化させてしまうこともない。従って、ヘモグロビン類の定量性により優れたものとなる。
シアン化物としては、例えば、シアン化カリウム、シアン化水素、シアン化ナトリウム、シアン化銀、シアン化水銀、シアン化銅、シアン化鉛、シアン化鉄、シアン化リチウム、シアン化アンモニウム等が挙げられる。
これらの三価のヘム鉄への結合剤のなかでも、アジ化ナトリウムが好適である。
有機酸としては、例えば、クエン酸、コハク酸、酒石酸、リンゴ酸等が挙げられる。
アミノ酸類としては、例えば、グリシン、タウリン、アルギニン等が挙げられる。
無機酸としては、例えば、塩酸、硝酸、硫酸、リン酸、ホウ酸、酢酸等が挙げられる。
また、緩衝液には、必要に応じて、界面活性剤、各種ポリマー、親水性の低分子化合物等が適宜添加されていてもよい。
有機酸としては、例えば、クエン酸、コハク酸、酒石酸、リンゴ酸等が挙げられる。
アミノ酸類としては、例えば、グリシン、タウリン、アルギニン等が挙げられる。
無機酸としては、例えば、塩酸、硝酸、硫酸、リン酸、ホウ酸、酢酸等が挙げられる。
また、緩衝液は、必要に応じて、界面活性剤、各種ポリマー、親水性の低分子化合物等が適宜添加されていてもよい。
イオン交換液体クロマトグラフィーとしては、公知の方法を用いることができる。例えば、ポンプを用いて溶離液を分離カラムに送液する際に、溶離液を、デガッサーを通した後に測定試料を注入して分離カラムに送り、分離カラムでヘモグロビン類を分離させて、溶出してきた溶出液中の分離成分を検出器により検出する方法が挙げられる。
充填剤粒子としては、無機系粒子、有機系粒子等が挙げられる。
無機系粒子としては、シリカ、ジルコニア等で構成される粒子が挙げられる。
有機系粒子としては、セルロース、ポリアミノ酸、キトサン等の天然高分子粒子や、ポリスチレン、ポリアクリル酸エステル等の合成高分子粒子が挙げられる。
陽イオン交換基としては、カルボキシル基、リン酸基、スルホン酸基等が挙げられる。
測定試料は、通常、界面活性剤等の溶血活性を有する物質を含む溶液により溶血された血液検体を希釈したものを用いる。測定試料の注入量は、血液検体の希釈倍率により異なるが、好ましくは0.1~100μL程度である。
即ち、本発明によれば、液体クロマトグラフィーによって、ヘモグロビン類を短時間で高精度に分離し、分析できる。
ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100を含有するリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
分離カラムとして、粒子表面にスルホン酸基を導入した陽イオン交換樹脂充填剤をカラム本体に充填したカラムを用いた。
HPLC装置には、オートサンプラーとしてSIL-20AC(島津製作所社製)、送液ポンプとしてLC-20AD(島津製作所社製)、デガッサーとしてDGU-20A5(島津製作所社製)、カラムオーブンとしてCTO-20AC(島津製作所社製)、検出器としてSPD-M20A(島津製作所社製)を用い、溶離液の流速を1.7mL/分、検出波長を415nm、測定試料注入量を10μLとした。
溶離液としては、0.5分までは溶離液1(60mmol/L過塩素酸ナトリウム、1mmol/L亜硝酸ナトリウム、1mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH5.4))にて溶出し、0.5分を超え1.0分までは溶離液2(10mmol/L過塩素酸ナトリウム、1mmol/L亜硝酸ナトリウム、1mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH7.0))にて溶出し、1.0分を超え1.1分までは溶離液3(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、1mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))にて溶出し、1.1分を超え1.5分までは溶離液1にて溶出して測定試料の測定を行った。
なお、HPLC装置の立ち上げ直後から連続して15回測定を行った。
測定試料は、実施例1と同様のものを用いた。
溶離液1を溶離液4(60mmol/L過塩素酸ナトリウム、1mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH5.4))、溶離液2を溶離液5(10mmol/L過塩素酸ナトリウム、1mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH7.0))に変更したこと以外は、実施例1と同様にして測定試料の測定を行った。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
分離カラムは実施例1と同様の分離カラムを用いた。
実施例1と同様のHPLC装置を用い、流速を1.7mL/分、検出波長を415nm、測定試料注入量を10μLとした。
溶離液は、第1溶離液として溶離液6(30mmol/L過塩素酸ナトリウム、1mmol/L亜硝酸ナトリウム、1mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))と第2溶離液として溶離液7(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、1mmol/L亜硝酸ナトリウム、1mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))とを用い、2液リニアグラジエントにて溶出して測定試料の測定を行った。第1溶離液と第2溶離液のグラジエント条件を図2に示した。図2は、第1溶離液と第2溶離液との合計量に対する第2溶離液の割合(重量%)を示している。また、得られたクロマトグラムを図3に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100、1mmol/L亜硝酸ナトリウム、1mmol/Lアジ化ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100、1mmol/L亜硝酸ナトリウム、1mmol/Lアジ化ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第2溶離液を、実施例1で用いた溶離液3(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、1mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図4に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液8(30mmol/L過塩素酸ナトリウム、10mmol/L亜硝酸ナトリウム、1mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、溶離液9(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、10mmol/L亜硝酸ナトリウム、1mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図5に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液10(30mmol/L過塩素酸ナトリウム、1mmol/L亜硝酸ナトリウム、10mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、溶離液11(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、1mmol/L亜硝酸ナトリウム、10mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図6に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液12(30mmol/L過塩素酸ナトリウム、10mmol/L亜硝酸ナトリウム、10mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、溶離液13(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、10mmol/L亜硝酸ナトリウム、10mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図7に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100、1mmol/Lフェリシアン化カリウム、1mmol/Lアジ化ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100、1mmol/Lフェリシアン化カリウム、1mmol/Lアジ化ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液14(30mmol/L過塩素酸ナトリウム、1mmol/Lフェリシアン化カリウム、1mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、溶離液15(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、1mmol/Lフェリシアン化カリウム、1mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図8に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100、1mmol/Lアジ化ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100、1mmol/Lアジ化ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液16(30mmol/L過塩素酸ナトリウム、1mmol/Lフェリシアン化ナトリウム、1mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、実施例1で用いた溶離液3(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、1mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図9に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100、1mmol/Lアジ化ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100、1mmol/Lアジ化ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液17(30mmol/L過塩素酸ナトリウム、1mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、実施例1で用いた溶離液3(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、1mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図10に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100、1mmol/L亜硝酸ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100、1mmol/L亜硝酸ナトリウムを含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液18(30mmol/L過塩素酸ナトリウム、1mmol/L亜硝酸ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、溶離液19(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、1mmol/L亜硝酸ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図11に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液20(30mmol/L過塩素酸ナトリウム、1mmol/Lフェリシアン化カリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、溶離液21(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図12に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液22(30mmol/L過塩素酸ナトリウム、25mmol/L亜硝酸ナトリウム、25mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、溶離液23(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、25mmol/L亜硝酸ナトリウム、25mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図13に示した。
グリコヘモグロビンコントロールレベル2(シスメックス社製)を200μLの注射用水で溶解した後、検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
また、ヘモグロビンSを含む血液検体を検体前処理液(0.1重量%トリトンX-100を含有する10mmol/Lリン酸緩衝液(pH7.0))で100倍に希釈したものを測定試料として用いた。
第1溶離液を、溶離液24(30mmol/L過塩素酸ナトリウム、50mmol/L亜硝酸ナトリウム、50mmol/Lアジ化ナトリウムを含む20mmol/Lリン酸緩衝液(pH5.4))に変更し、第2溶離液を、溶離液25(0.8重量%トリトンX-100、300mmol/L過塩素酸ナトリウム、50mmol/L亜硝酸ナトリウム、50mmol/Lアジ化ナトリウムを含む40mmol/Lリン酸緩衝液(pH8.0))に変更したこと以外は、実施例2と同様にして測定試料の測定を行った。得られたクロマトグラムを図14に示した。
図3~7(実施例2~6)において、ピーク(A)、ピーク(C)はシャープな単一ピークとして分離していることが確認された。図8(実施例7)はクロマトグラムに少しドリフトが確認されたために定量性が若干低下したが、ピーク同定は可能なレベルであった。一方、図9(実施例8)のピーク(A)、ピーク(C)はわずかに3峰性又は2峰性を示すピークとして検出されたが、問題の無い程度であった。
また、図3~9(実施例2~8)ではピーク(B)はピーク(A)から分離していることが確認されたが、図10(比較例2)ではグリコヘモグロビンコントロール2を含有する測定試料ではピーク(B)はピーク(A)から全く分離できておらず、ヘモグロビンSを含有する測定試料ではピーク(A)の後ろにピーク(B)がわずかにショルダーとして確認できる程度であった。同様の現象は他のヘモグロビン種に対しても起こりえるものと考えられ、本発明を用いることで含有量の多いヘモグロビン種に隣接したピークを高精度に分離させ易くなる。
図11、12(比較例3、4)では亜硝酸ナトリウム又はフェリシアン化カリウムによりメト化されたヘモグロビンがピークとして検出されているが、ヘモグロビン類の分解物とみられるピークが検出された。
図13、14(実施例9、10)は亜硝酸ナトリウムとアジ化ナトリウムが共存していることから、単一ピークを形成しているものの、添加量が多過ぎるために溶出時間が早くなりすぎていた。しかしながら、単一ピークが形成されているので、緩衝剤濃度等の他の条件を調整することで、定量性を確保することが可能である。
Claims (8)
- 液体クロマトグラフィーを用いたヘモグロビン類の分析方法であって、
予め検体を酸化剤及び三価のヘム鉄への結合剤で処理することを特徴とするヘモグロビン類の分析方法。 - 酸化剤は、ヘモグロビンをメト化させる物質であることを特徴とする請求項1記載のヘモグロビン類の分析方法。
- 酸化剤は、亜硝酸塩であることを特徴とする請求項2記載のヘモグロビン類の分析方法。
- 酸化剤は、亜硝酸ナトリウムであることを特徴とする請求項3記載のヘモグロビン類の分析方法。
- 三価のヘム鉄への結合剤は、メトヘモグロビン中の三価の鉄に結合する物質であることを特徴とする請求項1記載のヘモグロビン類の分析方法。
- 三価のヘム鉄への結合剤は、アジ化物であることを特徴とする請求項5記載のヘモグロビン類の分析方法。
- 三価のヘム鉄への結合剤は、アジ化ナトリウムであることを特徴とする請求項6記載のヘモグロビン類の分析方法。
- 液体クロマトグラフィーとして陽イオン交換液体クロマトグラフィーを用いることを特徴とする請求項1、2、3、4、5、6又は7記載のヘモグロビン類の分析方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/635,969 US20130130391A1 (en) | 2010-03-31 | 2011-03-22 | Method of analyzing hemoglobins |
JP2012509398A JP5875160B2 (ja) | 2010-03-31 | 2011-03-22 | ヘモグロビン類の分析方法 |
ES11765385T ES2961300T3 (es) | 2010-03-31 | 2011-03-22 | Método para analizar hemoglobinas |
EP11765385.7A EP2562539B1 (en) | 2010-03-31 | 2011-03-22 | Method of analyzing hemoglobins |
CN201180014727.XA CN102893147B (zh) | 2010-03-31 | 2011-03-22 | 血红蛋白类的分析方法 |
KR1020127028405A KR101810264B1 (ko) | 2010-03-31 | 2011-03-22 | 헤모글로빈류의 분석 방법 |
US14/508,143 US9304139B2 (en) | 2010-03-31 | 2014-10-07 | Method of analyzing hemoglobins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010083726 | 2010-03-31 | ||
JP2010-083726 | 2010-03-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/635,969 A-371-Of-International US20130130391A1 (en) | 2010-03-31 | 2011-03-22 | Method of analyzing hemoglobins |
US14/508,143 Continuation US9304139B2 (en) | 2010-03-31 | 2014-10-07 | Method of analyzing hemoglobins |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011125484A1 true WO2011125484A1 (ja) | 2011-10-13 |
Family
ID=44762438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/056816 WO2011125484A1 (ja) | 2010-03-31 | 2011-03-22 | ヘモグロビン類の分析方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20130130391A1 (ja) |
EP (1) | EP2562539B1 (ja) |
JP (1) | JP5875160B2 (ja) |
KR (1) | KR101810264B1 (ja) |
CN (1) | CN102893147B (ja) |
ES (1) | ES2961300T3 (ja) |
WO (1) | WO2011125484A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019203302A1 (ja) * | 2018-04-18 | 2019-10-24 | 積水メディカル株式会社 | ヘモグロビン分析方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103913454B (zh) * | 2014-04-04 | 2017-01-25 | 重庆医科大学 | 一种快速检测高铁血红蛋白血含量比色卡的制备方法 |
JP2016027326A (ja) * | 2014-06-26 | 2016-02-18 | アークレイ株式会社 | 測定方法、測定装置および溶離液 |
JP7184054B2 (ja) * | 2018-01-11 | 2022-12-06 | 東洋紡株式会社 | 測定試料希釈液およびキットおよび測定方法 |
CN113009022B (zh) * | 2018-12-29 | 2023-04-28 | 江山德瑞医疗科技有限公司 | 一种测定全血中糖化血红蛋白的方法 |
CN110779914B (zh) * | 2019-11-05 | 2022-05-20 | 湖南科技大学 | 基于血红蛋白与四碳或五碳二元酸复合物试剂盒制备方法 |
EP4119941A4 (en) * | 2020-03-13 | 2024-04-10 | Sekisui Medical Co Ltd | HEMOGLOBIN TEST PROCEDURES |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5644851A (en) * | 1979-09-21 | 1981-04-24 | Mitsubishi Chem Ind Ltd | Measurement of glycocylhemoglobin |
JPS5879163A (ja) * | 1981-10-16 | 1983-05-12 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 糖結合ヘモグロビンの測定法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5844985B2 (ja) * | 1976-04-13 | 1983-10-06 | 中外製薬株式会社 | ヘモグロビン測定用試薬 |
US4108603A (en) * | 1977-05-18 | 1978-08-22 | Purdue Research Foundation | Method for rapid analysis of hemoglobin variants by high speed liquid chromatography |
JPS55162060A (en) * | 1979-06-04 | 1980-12-17 | Mitsubishi Chem Ind Ltd | Measuring method for glycosyl hemoglobin |
US4260516A (en) * | 1979-12-07 | 1981-04-07 | Abbott Laboratories | Glycosylated hemoglobin standards |
US4970171A (en) * | 1987-11-09 | 1990-11-13 | Miles Inc. | Denaturant reagents for convenient determination of hemoglobin derivatives in blood |
DE4206932A1 (de) * | 1992-03-05 | 1993-09-09 | Boehringer Mannheim Gmbh | Immunologische methode zur bestimmung eines haemoglobinderivates |
US5223219A (en) * | 1992-04-10 | 1993-06-29 | Biotrack, Inc. | Analytical cartridge and system for detecting analytes in liquid samples |
JP4033534B2 (ja) | 1997-12-03 | 2008-01-16 | アルフレッサファーマ株式会社 | ヒトヘモグロビンの安定化方法 |
WO2000008460A1 (fr) * | 1998-08-07 | 2000-02-17 | Sekisui Chemical Co., Ltd. | Procede de determination d'hemoglobines |
US6184228B1 (en) * | 1999-05-25 | 2001-02-06 | Anadys Pharmaceuticals, Inc. | Anti-sickling agents: selection methods and effective compounds |
JPWO2002021142A1 (ja) * | 2000-09-07 | 2004-01-15 | 和光純薬工業株式会社 | 総ヘモグロビン及び糖化ヘモグロビンの測定方法 |
JP2003014714A (ja) * | 2001-06-29 | 2003-01-15 | Sekisui Chem Co Ltd | ヘモグロビン類の測定方法 |
JP3898947B2 (ja) | 2001-12-27 | 2007-03-28 | 栄研化学株式会社 | ヘムタンパク質の安定化方法およびこれに用いる保存溶液 |
JP5422108B2 (ja) | 2007-10-16 | 2014-02-19 | 栄研化学株式会社 | ヘムタンパク質の安定化方法及び保存溶液 |
-
2011
- 2011-03-22 EP EP11765385.7A patent/EP2562539B1/en active Active
- 2011-03-22 KR KR1020127028405A patent/KR101810264B1/ko active IP Right Grant
- 2011-03-22 ES ES11765385T patent/ES2961300T3/es active Active
- 2011-03-22 JP JP2012509398A patent/JP5875160B2/ja active Active
- 2011-03-22 US US13/635,969 patent/US20130130391A1/en not_active Abandoned
- 2011-03-22 CN CN201180014727.XA patent/CN102893147B/zh active Active
- 2011-03-22 WO PCT/JP2011/056816 patent/WO2011125484A1/ja active Application Filing
-
2014
- 2014-10-07 US US14/508,143 patent/US9304139B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5644851A (en) * | 1979-09-21 | 1981-04-24 | Mitsubishi Chem Ind Ltd | Measurement of glycocylhemoglobin |
JPS5879163A (ja) * | 1981-10-16 | 1983-05-12 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 糖結合ヘモグロビンの測定法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019203302A1 (ja) * | 2018-04-18 | 2019-10-24 | 積水メディカル株式会社 | ヘモグロビン分析方法 |
JP6600123B1 (ja) * | 2018-04-18 | 2019-10-30 | 積水メディカル株式会社 | ヘモグロビン分析方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5875160B2 (ja) | 2016-03-02 |
EP2562539B1 (en) | 2023-09-27 |
JPWO2011125484A1 (ja) | 2013-07-08 |
CN102893147B (zh) | 2015-10-21 |
EP2562539A4 (en) | 2015-01-28 |
US20130130391A1 (en) | 2013-05-23 |
KR101810264B1 (ko) | 2017-12-18 |
EP2562539A1 (en) | 2013-02-27 |
KR20130054951A (ko) | 2013-05-27 |
ES2961300T3 (es) | 2024-03-11 |
CN102893147A (zh) | 2013-01-23 |
US20150024503A1 (en) | 2015-01-22 |
US9304139B2 (en) | 2016-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5875160B2 (ja) | ヘモグロビン類の分析方法 | |
Staub et al. | Analysis of hemoglobin‐based oxygen carriers by CE‐UV/Vis and CE‐ESI‐TOF/MS | |
JP6600123B1 (ja) | ヘモグロビン分析方法 | |
JP5462841B2 (ja) | ヘモグロビンの分析方法 | |
JP5013560B2 (ja) | ヘモグロビンsの分析方法、及び、ヘモグロビンa2の分析方法 | |
Khalikova et al. | A high-performance liquid chromatography method with pre-column derivatization for the simultaneous determination of reduced glutathione, carnosine and taurine | |
Pucciarini et al. | Optimized one-pot derivatization and enantioseparation of cysteine: Application to the study of a dietary supplement | |
EP2960648B1 (en) | Measurement method, measurement apparatus, and eluent for the analysis of hemoglobins | |
Konz et al. | Incorporation of 57 Fe-isotopically enriched in apoferritin: formation and characterization of isotopically enriched Fe nanoparticles for metabolic studies | |
Kuang et al. | Quantitative determination of ɛ-N-carboxymethyl-l-lysine in human plasma by liquid chromatography–tandem mass spectrometry | |
EP4119941A1 (en) | Hemoglobin assay method | |
JP2002082105A (ja) | 液体クロマトグラフィー用充填剤、カラム、及びそれを用いたヘモグロビン類の測定方法 | |
CN114062565B (zh) | 一种检测样品中含dota环或nota环的化合物的方法 | |
JP2021179337A (ja) | ヘモグロビン分析方法 | |
JP2000146941A (ja) | ヘモグロビン類の測定方法 | |
EP4011473A1 (en) | Method for measurement of hemoglobin | |
CN117805272A (zh) | 一种糖化血红蛋白检测试剂盒及一种糖化血红蛋白检测方法 | |
Andersson | Method development for the determination of thiols using HPLC with fluorescence detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180014727.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11765385 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012509398 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011765385 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127028405 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13635969 Country of ref document: US |